Taysha Gene Therapies shares are trading lower after Canaccord Genuity maintained a Buy rating on the stock but lowered its price target from $13 to $7.
Portfolio Pulse from Benzinga Newsdesk
Taysha Gene Therapies' shares are trading lower after Canaccord Genuity maintained a Buy rating on the stock but lowered its price target from $13 to $7.
August 16, 2023 | 7:10 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Taysha Gene Therapies' stock price is trading lower due to Canaccord Genuity's decision to lower its price target from $13 to $7, despite maintaining a Buy rating.
The news directly impacts Taysha Gene Therapies as it is about a reduction in the price target of its stock by Canaccord Genuity. This could lead to a decrease in the stock price in the short term as it may shake investor confidence, despite the maintained Buy rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100